BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 7779855)

  • 1. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semiquantitative measurement of cytokine messenger RNA in endomyocardium and peripheral blood mononuclear cells from human heart transplant recipients.
    Lagoo AS; George JF; Naftel DC; Griffin AK; Kirklin JK; Lagoo-Deenadayalan S; Hardy KJ; Savunen T; McGiffin DC
    J Heart Lung Transplant; 1996 Feb; 15(2):206-17. PubMed ID: 8672525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy.
    Fisher PE; Suciu-Foca N; Ho E; Michler RE; Rose EA; Mancini D
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1156-61. PubMed ID: 8719463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.
    van Gelder T; Baan CC; Balk AH; Knoop CJ; Holweg CT; van der Meer P; Mochtar B; Zondervan PE; Niesters HG; Weimar W
    Transplantation; 1998 Feb; 65(3):405-10. PubMed ID: 9484761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
    Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
    J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation.
    Baan CC; Balk AH; van Riemsdijk IC; Vantrimpont PJ; Maat AP; Niesters HG; Zondervan PE; van Gelder T; Weimar W
    Transplantation; 2003 May; 75(10):1704-10. PubMed ID: 12777860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.
    van Gelder T; Balk AH; Jonkman FA; Zietse R; Zondervan P; Hesse CJ; Vaessen LM; Mochtar B; Weimar W
    Transplantation; 1996 Jul; 62(1):51-5. PubMed ID: 8693545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental and clinical allogeneic heart transplant rejection: correlations between histology and immune reactivity detected by cytokine messenger RNA.
    Normann SJ; Peck AB; Staples ED; Salomon DR; Mills RM
    J Heart Lung Transplant; 1996 Aug; 15(8):778-89. PubMed ID: 8878760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3.
    Kemnitz J; Cremer J; Schaefers HJ; Restrepo-Specht I; Haverich A; Uysal A; Heublein B; Wirth S
    J Heart Lung Transplant; 1991; 10(3):366-72. PubMed ID: 1906746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB; Renlund DG; Hammond EH; Wittwer CT; Yowell RL; DeWitt CW; Jones KW; Gay WA; Menlove RL; Bristow MR
    J Heart Lung Transplant; 1991; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
    van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
    Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
    [No Abstract]   [Full Text] [Related]  

  • 14. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
    Wabbijn M; Balk AH; van Domburg RT; Vantrimpont PJ; van Riemsdijk IC; Baan CC; Weimar W; van Gelder T
    Exp Clin Transplant; 2004 Jun; 2(1):201-7. PubMed ID: 15859929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different patterns in donor-specific production of T-helper 1 and 2 cytokines by cells infiltrating the rejecting cardiac allograft.
    van Besouw NM; Daane CR; Vaessen LM; Balk AH; Claas FH; Zondervan PE; Jutte NH; Weimar W
    J Heart Lung Transplant; 1995; 14(5):816-23. PubMed ID: 8800715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intragraft cytokine mRNA pattern reflects the efficacy of steroid antirejection therapy.
    Baan CC; Niesters HG; Balk AH; Mochtar B; Zondervan PE; Weimar W
    J Heart Lung Transplant; 1996 Dec; 15(12):1184-93. PubMed ID: 8981203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability and usefulness of immunofluorescence in heart transplantation.
    Bonnaud EN; Lewis NP; Masek MA; Billingham ME
    J Heart Lung Transplant; 1995; 14(1 Pt 1):163-71. PubMed ID: 7727465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction.
    Schowengerdt KO; Ni J; Denfield SW; Gajarski RJ; Radovancevic B; Frazier HO; Demmler GJ; Kearney D; Bricker JT; Towbin JA
    J Heart Lung Transplant; 1996 Feb; 15(2):111-23. PubMed ID: 8672514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.